These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29272266)

  • 21. Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study.
    Robinson Y; Olerud C; Willander J
    BMJ Open; 2017 Dec; 7(12):e016548. PubMed ID: 29288176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
    Frieder J; Kivelevitch D; Menter A
    Ther Adv Chronic Dis; 2018 Jan; 9(1):5-21. PubMed ID: 29344327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis.
    Erol K; Gok K; Cengiz G; Kilic G; Kilic E; Ozgocmen S
    Acta Reumatol Port; 2018; 43(1):32-39. PubMed ID: 29342471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab.
    Hoshina D; Haga N; Furuya K; Sakai M
    Clin Exp Dermatol; 2018 Aug; 43(6):718-719. PubMed ID: 29314197
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
    Puig L
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E; d'Oliveira I; Linz C; Lerchen V; Stemmler F; Simon D; Englbrecht M; Sticherling M; Rech J; Kleyer A; Schett G; Hueber AJ
    Arthritis Res Ther; 2018 Jul; 20(1):153. PubMed ID: 30053825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.
    Anzengruber F; Drach M; Maul JT; Kolios AG; Meier B; Navarini AA
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e274-e276. PubMed ID: 29356172
    [No Abstract]   [Full Text] [Related]  

  • 30. From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications.
    Perrotta FM; De Socio A; Scriffignano S; Lubrano E
    Expert Rev Clin Immunol; 2018 Mar; 14(3):207-213. PubMed ID: 29338498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
    Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting IL-17 in psoriatic arthritis.
    Wang EA; Suzuki E; Maverakis E; Adamopoulos IE
    Eur J Rheumatol; 2017 Dec; 4(4):272-277. PubMed ID: 29308283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients.
    de Stefano R; Frati E; de Quattro D; de Stefano L
    J Clin Rheumatol; 2018 Apr; 24(3):127-131. PubMed ID: 29293113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis.
    Kuusalo L; Puolakka K; Kautiainen H; Karjalainen A; Malmi T; Paimela L; Leirisalo-Repo M; Rantalaiho V;
    Clin Rheumatol; 2018 Jun; 37(6):1689-1694. PubMed ID: 29280011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guselkumab (Tremfya) for Psoriasis.
    JAMA; 2017 Dec; 318(24):2487-2488. PubMed ID: 29279926
    [No Abstract]   [Full Text] [Related]  

  • 37. How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis.
    Amin M; Lee EB; Wu JJ
    J Dermatolog Treat; 2019 Jun; 30(4):374-375. PubMed ID: 30086664
    [No Abstract]   [Full Text] [Related]  

  • 38. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
    Coates LC; Mease PJ; Gossec L; Kirkham B; Sherif B; Gaillez C; Mpofu S; Jugl SM; Karyekar C; Gandhi KK
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1529-1535. PubMed ID: 29409133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline patients' characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments.
    Xie KK; Braue A; Martyres R; Varigos G
    Australas J Dermatol; 2018 Nov; 59(4):e247-e252. PubMed ID: 29315464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of education and telephone counseling on adherence to treatment and challenges experienced in anti-TNF-α treatment: a pilot study.
    Ozkaraman A; Alparslan GB; Babadağ B; Kaşifoğlu T; Baydemir C
    Contemp Nurse; 2018 Feb; 54(1):108-119. PubMed ID: 29310538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.